nimodipine has been researched along with Auditory Vertigo in 4 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Due to its proposed vasoactive and neuroprotective effects, nimodipine may play a role in the treatment of a number of otolaryngic pathologies including VS, Ménière's disease, peripheral vertigo, RLN injury, and facial weakness after maxillofacial surgery." | 4.98 | Nimodipine for the treatment of otolaryngic indications. ( Levy, ZD; Shafeeq, H; Sin, JH, 2018) |
| " A total of 113 medical records were analysed; 53 patients received betahistine-dihydrochloride at on-label dosage (32 mg die) for six months, and 60 patients were treated with the same regimen and nimodipine (40 mg die) as an add-therapy during the same period." | 1.38 | Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: a 10-year experience. ( Aggazzotti Cavazza, E; Alicandri Ciufelli, M; Barillari, MR; Genovese, E; Monzani, D; Neri, V; Presutti, L, 2012) |
| "Nimodipine is a highly lipophilic, centrally acting calcium channel blocker." | 1.29 | Use of nimodipine in the medical treatment of Menière's disease: clinical experience. ( Hirsch, BE; Kamerer, DB; Lassen, LF, 1996) |
| "12 patients showed sudden deafness with a history of one day up to more than 20 years." | 1.27 | [Nimodipine (Bay e 9736) a new therapy concept in diseases of the inner ear?]. ( Theopold, HM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sin, JH | 1 |
| Shafeeq, H | 1 |
| Levy, ZD | 1 |
| Monzani, D | 1 |
| Barillari, MR | 1 |
| Alicandri Ciufelli, M | 1 |
| Aggazzotti Cavazza, E | 1 |
| Neri, V | 1 |
| Presutti, L | 1 |
| Genovese, E | 1 |
| Lassen, LF | 1 |
| Hirsch, BE | 1 |
| Kamerer, DB | 1 |
| Theopold, HM | 1 |
1 review available for nimodipine and Auditory Vertigo
| Article | Year |
|---|---|
Nimodipine for the treatment of otolaryngic indications.
Topics: Calcium Channel Blockers; Humans; Meniere Disease; Neuroprotective Agents; Nimodipine; Otorhinolaryn | 2018 |
3 other studies available for nimodipine and Auditory Vertigo
| Article | Year |
|---|---|
Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: a 10-year experience.
Topics: Adult; Betahistine; Drug Therapy, Combination; Female; Humans; Male; Meniere Disease; Middle Aged; N | 2012 |
Use of nimodipine in the medical treatment of Menière's disease: clinical experience.
Topics: Calcium Channel Blockers; Female; Hair Cells, Auditory; Humans; Male; Meniere Disease; Nimodipine; R | 1996 |
[Nimodipine (Bay e 9736) a new therapy concept in diseases of the inner ear?].
Topics: Adult; Aged; Auditory Threshold; Calcium Channel Blockers; Female; Hearing Loss, Noise-Induced; Hear | 1985 |